Mathur I S, Gupta H P, Srivastava S K, Singh S, Madhu K, Khanna N M
J Med Microbiol. 1985 Dec;20(3):387-92. doi: 10.1099/00222615-20-3-387.
Conventional chemotherapy of tuberculosis and leprosy requires rifampicin to be administered orally. The long period of treatment and adverse side effects of the drug lead to poor compliance. To overcome this, subdermal implants incorporating rifampicin in pure and micro-encapsulated forms with biodegradable material were used as a new drug delivery system in experimental tuberculosis of guinea pigs. Two experiments were performed with 45-mg and 100-mg drug implants. Progress of infection was followed at intervals by studying necropsy scores and weights of the organs of predilection and levels of the drug in the blood were determined. There was a constant and sustained release of the drug in therapeutic concentrations for 30 and 50 days until the implants were completely assimilated without causing any damage to the implant site. The importance of multiple implants at long intervals is discussed.
结核病和麻风病的传统化疗需要口服利福平。该药物治疗周期长且有副作用，导致患者依从性差。为克服这一问题，将利福平以纯形式和微囊化形式与可生物降解材料制成的皮下植入物用作豚鼠实验性结核病的新型药物递送系统。使用45毫克和100毫克药物植入物进行了两项实验。通过研究尸检评分、好发器官重量并测定血液中的药物水平，定期跟踪感染进展。药物在治疗浓度下持续释放30天和50天，直到植入物完全被吸收，且未对植入部位造成任何损伤。讨论了长时间间隔多次植入的重要性。
